Vito T.
- Country
- Italy
- Department
- Cystic Fibrosis Center
Research Overview
- Phase 2 Randomized Double‑Blind Study of VX-828/Deutivacaftor With and Without Tezacaftor in Adults with Cystic Fibrosis
- A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18Years or Older (CHOICES)
- Evaluation of Efficacy, Safety, and Pharmacokinetics of Inhaled ETD001 in Cystic Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 65 of 149 partner sites.
Specializations
Respiratory Medicine
Specializes in the treatment of cystic fibrosis, with particular focus on rare genetic variations of the disease. The investigator has extensive experience in evaluating novel therapeutic approaches for CF patients.
- Rare CFTR mutations
- Genetic respiratory disorders
- Advanced therapeutic interventions
Demonstrates expertise in assessing treatment responses in patients with specific genetic variants of CF.
Personalized Medicine
Focuses on targeted therapeutic approaches based on individual patient characteristics, particularly in the context of rare genetic mutations.
- Organoid response assessment
- Mutation-specific treatments
- Biomarker evaluation
Utilizes advanced diagnostic methods to determine optimal treatment strategies for individual patients.
Clinical Research
Conducts complex clinical trials evaluating innovative therapeutic combinations for respiratory conditions.
- Multi-drug therapeutic approaches
- Treatment efficacy assessment
- Safety evaluation protocols
Specializes in crossover study designs and long-term treatment evaluation methods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.